SPONSORED BY SICA MEDIA AND DISSEMINATED ON BEHALF OF CYBIN D/B/A HELUS PHARMA*

Todays Alert: Cybin D/B/A Helus Pharma (Nasdaq: HELP)

🚨 TODAY: Helus put fresh numbers behind the story. In their fiscal Q3 update, the company reported $195.1M in cash as of Dec. 31, 2025, while reiterating that the Phase 2 HLP004 (GAD) topline readout is expected in Q1 2026. In other words: the balance sheet looks built to carry them into the next catalyst, and the catalyst window just got put back on the calendar in bold. (6)

If you have been paying attention to our alerts over the last few months, you’ll have noticed that we tend to spend a significant portion of our time in the pharma space—researching, talking to industry analysts, and picking the brains of leaders to find the most exciting and high-potential entities. 

We aren't looking for the "safe" legacy players who move at the speed of a tectonic plate. We are looking for the disruptors.

Right now, if you aren’t paying attention to what is happening with Cybin D/B/A Helus Pharma (Nasdaq: HELP), you are effectively choosing to ignore the most significant medical pivot of the decade. This isn't just another biotech story; this is the commercialization of a new paradigm in human wellness.

(1)

The Evolution: From "Concept" to "Cures" (1)(2)(3)

Let’s be real: for years, the mental health sector was a bit of a "wait and see" game. Plenty of "cool" science, but not enough "commercial" muscle. That changed forty-eight hours ago.

The company formerly known as Cybin has officially matured into its final, most potent form: Cybin D/B/A Helus Pharma (Nasdaq: HELP). The name—pronounced "Heal-Us"—is a direct signal to the market that they are moving beyond the R&D lab and into the clinic. They didn't just change the logo; they shifted their entire weight onto the Nasdaq to ensure they have the liquidity and visibility to dominate the field. If you missed the transition from the NYSE American to the big leagues of the Nasdaq Global Market, consider this your official wake-up call.

The "Cola" Factor: A Heavyweight Joins the Ring (1)(2)(3)

On February 10, the company dropped a piece of news that sent ripples through the neuro-pharmaceutical community. They’ve appointed Michael Cola as the new Chief Executive Officer.

In this world, leadership is everything. You don't bring in a veteran like Cola—the man who scaled CNS franchises at Shire and Astra-Merck—unless you are preparing to conquer the market. This isn't a "placeholder" hire. This is a "let's build a multi-billion-dollar commercial engine" hire. His arrival is the clearest sign yet that the "experimental" phase of this technology is dead, and the "delivery" phase has begun.

The Fortress: A Comparison of Intellectual Property (1)(2)(3)

One of the biggest mistakes people make when looking at this space is assuming all "novel molecules" are created equal. They aren't. In fact, most are easily copied. Cybin D/B/A Helus Pharma (Nasdaq: HELP), however, has built a defensive moat that would make a medieval king blush.

While competitors are often sitting on a handful of filings, Cybin D/B/A Helus Pharma (Nasdaq: HELP) has aggressively secured a sector-leading estate:

350+ Global Patent Applications: Covering everything from molecule composition to specific delivery methods.

100+ Granted Patents: These aren't just "pending" hopes; they are active, legal protections.

Exclusivity until 2041: Their core assets are protected for nearly two decades.

In a direct comparison with other players in the space, Helus has focused on deuterated compounds. By swapping out hydrogen atoms for deuterium, they’ve created molecules that are more stable, more predictable, and—most importantly—completely proprietary. You can’t just "genericize" their breakthrough because the chemistry itself is locked down under their unique IP.

(3)

The Pipeline: Two Rockets on the Launchpad (1)(2)(3)

If the IP is the fortress, the pipeline is the artillery. We are currently staring down the barrel of two massive clinical milestones in 2026 that could redefine the valuation of this entity overnight.

HLP003 (The Depression Destroyer): This is a proprietary deuterated psilocin analog currently in Phase 3 trials, the final hurdle before a potential FDA submission. It has already been granted Breakthrough Therapy Designation. That is essentially the FDA’s way of saying, "We agree that current treatments for Major Depressive Disorder (MDD) are failing, and this looks like the real deal." Topline data for the "APPROACH" study is expected in Q4 2026.

HLP004 (The Anxiety Answer): This is a deuterated DMT analog targeting Generalized Anxiety Disorder (GAD). Here is the kicker: Phase 2 topline data is expected this quarter. We are talking about a major value-inflection point that could land on your desk any day now.

(3)

Why the "Short-Trip" Matters (1)(2)(3)

The biggest bottleneck in this industry has always been clinic time. No one wants to spend 6–8 hours in a doctor's office. Cybin D/B/A Helus Pharma (Nasdaq: HELP) solved this by engineering their molecules to provide the same neuroplastic benefits in a 90-minute window.

Think about the math: a clinic using Helus' protocols can treat four times as many people per day as a clinic using standard molecules. That isn't just better medicine; it’s a better business model. It is the only way to scale these treatments to the millions of people who actually need them.

(3)

The Valuation Gap (4)(5)

Currently, the market seems to be sleepwalking. Despite the massive de-risking that occurred with the Michael Cola appointment and the $100 million in fresh capital secured via their recent equity program, the company is still positioned at a fraction of its consensus target price.

Analysts at major firms have placed price targets on this entity that represent a nearly 600% potential upside from current levels. When was the last time you saw a "discount" that massive on a company with Phase 3 assets and a Hall of Fame CEO?

(5)

The window to get ahead of the Phase 2 GAD data is closing fast. 

The Verdict: Don’t Get Left Behind 

History is full of people who saw the writing on the wall but waited for "more confirmation." By the time the confirmation arrives, the "entry point" is gone. 

Cybin D/B/A Helus Pharma (Nasdaq: HELP) is one of the most advanced, best-protected, and most strategically led entities in the mental health revolution.

The 2026 milestones are coming. The leadership is in place. The IP moat is dug. The only question left is whether you’re going to be there for this shift or a spectator.

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:

1. https://finance.yahoo.com/news/helus-pharma-appoints-michael-cola-123000490.html
2. https://www.helus.com/
3. https://bit.ly/4txxec7
4. https://finance.yahoo.com/quote/HELP/
5. https://finance.yahoo.com/quote/HELP/analyst-insights/
6. https://finance.yahoo.com/news/helus-pharma-reports-third-quarter-123100330.html
 

Paid Promotion. Momentum Media LLC has been hired for a period beginning on 02/12/2026 and ending on 02/13/2026 (the “Campaign”) to publicly disseminate information about Cybin D/B/A Helus Pharma (HELP:US). Momentum Media LLC has been compensated $5,000 and are owed an additional $0 for the Campaign. Please read Momentum Media LLC’s complete disclaimer at https://markettips.net/disclaimer/ which includes important information. Emojis, graphics and/or images used herein have no specific or implied meaning, and are used for artistic purposes only. Nothing contained herein is financial advice. Momentum Media LLC is not an analyst, st.o.ck broker, financial adviser or st.o.ck picker nor is it qualified to act in the capacity of any of the foregoing. Information herein is a paid advertisement and should not be relied upon as accurate or complete.